Michael Thomas Durheim

Michael Thomas Durheim holds academic appointments as a Lecturer at the Institute of Clinical Medicine (2020-2021) and Senior Consultant in Respiratory Medicine at Oslo University Hospital-Rikshospitalet (2016–present). He earned his M.D. from Duke University School of Medicine (USA) and a Dr.Philos. in Pulmonary Medicine from the University of Oslo (2022). His research focuses on interstitial lung diseases, lung transplantation outcomes, and post-COVID-19 pulmonary sequelae.

Education:

• M.D., Duke University School of Medicine, USA
• Dr.Philos., Institute of Clinical Medicine, University of Oslo

Research Interests:

• Interstitial lung diseases (e.g., idiopathic pulmonary fibrosis)
• Outcomes in lung transplantation
• Post-COVID-19 cardiac and pulmonary complications
• Complement pathway in pulmonary fibrosis pathogenesis

Publications Trends: Recent works emphasize clinical trials (e.g., CleanUP-IPF trial), post-transplant complications, and the impact of antimicrobial therapy in pulmonary fibrosis. His post-COVID studies explore long-term cardiac and respiratory outcomes using imaging and biomarkers.

Awards: None explicitly listed.

Advising & Grants: Active in clinical trial design (e.g., randomized controlled trials on antimicrobial therapy) and translational research in lung transplantation. Collaborates on national and international studies.

Labs/Teams: Member of the "Lung transplantation and inflammation" research group at the University of Oslo, focusing on translational and clinical studies in respiratory medicine.